1632 – PSMA PET/CT imaging for informing treatment of patients with prostate cancer

Page last updated: 20 October 2021

Application Detail

Description of Medical Service

Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) and Computed Tomography (CT) imaging involves the administration of one of several radiopharmaceuticals that share the characteristic of highly specific binding to PSMA. PSMA is present in much higher concentrations in prostate cancer cells than in normal prostate and other tissues. This overexpression of PSMA by prostate cancers allows for highly specific detection of tumour sites throughout the body. The advantages of PSMA PET/CT are particularly apparent for men in whom spread has occurred outside the prostate gland both at staging and later in the course of the disease and for whom prognosis is significantly impaired.

Description of Medical Condition

Prostate cancer is the most commonly diagnosed cancer (>19,000 cases pa) and second most common cause of cancer death (>3,000 pa) in Australian men.Between 1986–1990 and 2011–2015, five-year relative survival from prostate cancer improved from 59% to 95%. More than 90,000 Australians are estimated to be living with prostate cancer.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1246 KB)
Application Form (Word 135 KB)

Consultation Survey

Consultation Survey (PDF 560 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation

PICO Confirmation (PDF 1175 KB)
PICO Confirmation (Word 332 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 703 KB)
Public Summary Document (Word 266 KB)

Meetings for this Application


13 August 2020


10-11 June 2021


29-30 July 2021